

1 September 2022

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

Bod Australia Limited (ASX: BOD)
Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)

This notice is given by Bod Australia Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **Bod**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Act**).

Bod has announced a pro rata, non-accelerated, non-renounceable entitlement offer (**Entitlement Offer**) of four fully paid Bod ordinary shares (**Shares**) for every 17 Shares held by eligible Bod shareholders with a registered address in Australia or New Zealand as at 7.00pm (Sydney time) on Tuesday, 6 September 2022.

The Entitlement Offer is being conducted at an issue price of \$0.08 per Share (**Offer Price**) to raise up to approximately \$2.0 million. Accordingly, a total of up to approximately 24.92 million Shares will be issued under the Entitlement Offer.

The Entitlement Offer is being partially underwritten by Chairman David Baker, up to \$100,000 worth of shortfall Shares (being 1,250,000 Shares).

In conjunction with the Entitlement Offer, the Company is undertaking an institutional placement of Shares to raise \$1.5 million via the issue of 18,750,000 Shares.

Bod advises that:

1. the Shares to be issued pursuant to the Entitlement Offer will be offered for issue without disclosure under Part 6D.2 of the Act;
2. this notice is being given under section 708AA(2)(f) of the Act;
3. as at the date of this notice Bod has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to BOD; and
 - b. sections 674 and 674A of the Act;
4. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section 708AA(7)(d) of the Act; and
5. the potential effect that the Entitlement Offer will have on the control of Bod and the consequences of that effect, will depend on a number of factors, including investor

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 T +61 2 9199 5018 E info@bodscience.com W bodscience.com

demand and existing shareholdings. At this time, the issue of Shares under the Entitlement Offer is not expected to have a material effect or consequence on the control of Bod given:

- a. the Entitlement Offer is structured as a pro-rata issue at an offer ratio of four new Shares for every 17 existing Shares;
- b. the Entitlement Offer is only partially underwritten, up to a maximum of 1,250,000 Shares;
- c. the Entitlement Offer will be undertaken in conjunction with a placement of Shares at the Offer Price which will involve the issue of 18,750,000 Shares (which will not be entitled to participate in the Entitlement Offer); and
- d. the current level of holdings of substantial holders (based on substantial holding notices that have been given to Bod and lodged with ASX on or before the date of this notice).

Authorised for release by the Company Secretary of Bod Australia Limited.

ENDS

Further Information

Investors:

Stephen Kelly
Company Secretary
Info@bodaustralia.com
+61 415 719 695

Media:

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About Bod Australia

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information on BOD please visit <https://bodscience.com/>

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 T +61 2 9199 5018 E info@bodscience.com W bodscience.com

IMPORTANT INFORMATION

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 **T** +61 2 9199 5018 **E** info@bodscience.com **W** bodscience.com